>One of the medications, atomoxetine, approved by the U.S. Food and Drug Administration (FDA) in 2002 for attention-deficit/hyperactivity disorder, increases le

>One of the medications, atomoxetine, approved by the U.S. Food and Drug Administration (FDA) in 2002 for attention-deficit/hyperactivity disorder, increases levels of the excitatory neurotransmitter norepinephrine by blocking its reuptake from neuronal synapses. Guessing this will never see the light of day as insomnia is going to be a major side effect. Preventing sleep apnea by preventing sleep is not exactly a great trade-off.